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3MicroAbstract
ABCG2/BCRP, expression of which is commonly associated with chemoresistance, was 
found to be significant up-regulated in tumour cells after neoadjuvant endocrine therapy in 
three separate cohorts of primary breast cancer patients. Endocrine-induced up-regulation of 
ABCG2/BCRP in vitro was associated with resistance to subsequent treatment with 
chemotherapy.  
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4ABSTRACT
Introduction: Neoadjuvant treatments for primary breast cancer are becoming more 
common, however little is known about how these impact on response to subsequent 
adjuvant therapies. Conveniently, neoadjuvant therapy provides opportunities to consider 
this question, by studying therapy-induced expression changes using comparisons between 
pre- and post-treatment samples. These data are relatively lacking in the context of 
neoadjuvant endocrine therapy, as opposed to the more common neoadjuvant 
chemotherapy. Here, we investigate the relevance of expression of the xenobiotic 
transporter ABCG2/BCRP, a gene/protein associated with chemoresistance, in the context 
of neoadjuvant endocrine therapy and particularly with reference to subsequent 
chemotherapy treatment. 
Materials and methods: ABCG2/BCRP expression was assessed by 
immunohistochemistry or by expression arrays in matched patient samples pre- and post-
neoadjuvant endocrine therapy. Cell culture was used to model the impact of endocrine 
therapy induced changes in ABCG2/BCRP on subsequent chemotherapy response, using 
Western blots, qPCR, survival assays and cell cycle analyses. 
Results: ABCG2/BCRP was commonly and significantly up-regulated in breast cancers after 
treatment with neoadjuvant endocrine therapy in three separate cohorts encompassing a 
total of 200 patients. Treatment with the endocrine therapeutic tamoxifen similarly induced 
ABCG2/BCRP up-regulation in a relevant model cell line, the estrogen receptor positive line 
T47D. Critically, this up-regulation was associated with significantly increased 
chemoresistance to subsequent treatment with epirubicin, an anthracycline commonly used 
in breast cancer adjuvant chemotherapy. 
Conclusion: Our data suggest that NAET may induce poor responses to adjuvant 
chemotherapy, and therefore that clinical outcomes following this treatment sequence 
warrant further study.  
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5Introduction
Use of neoadjuvant therapies for treatment of primary breast cancer is becoming more 
frequent for at least two reasons. First, these therapies can down-stage tumours, thereby 
enabling increase rates of breast conserving surgery as opposed to mastectomy1. Secondly, 
they can provide opportunities to assess tumour responses to specific therapeutics using 
longitudinal imaging and clinical assessments, therefore allowing switching to potentially 
more effective treatment regimens if initial responses are deemed inadequate2. 
Chemotherapy is the most common neoadjuvant approach, however neoadjuvant endocrine 
therapy (NAET) is preferred in some patients with ER-positive disease3, and is particularly 
accepted in patients who are elderly, frail or have problematic co-morbidities and therefore 
extended non-surgical management may be desirable4. Increased consideration of NAET in 
selected patients has recently been recommended5, 6 on account of similar overall response 
rates to neoadjuvant chemotherapy3 with lower toxicity7, although it should be noted that 
complete pathological responses are far rarer with NAET. It has also been suggested that 
clinical or molecular responses to NAET should be integrated with other factors to stratify 
patients to appropriate adjuvant treatments such as chemotherapy8, 9.
Use of neoadjuvant therapies provides powerful opportunities to assess molecular 
responses of cancers to specific therapies by comparison between matched pre-treatment 
diagnostic samples and post-treatment resection samples. These comparisons are quite 
prevalent in the context of neoadjuvant chemotherapy, both at the level of individual genes 
or at the transcriptome level10-12, but many fewer studies are available for NAET, with only a 
handful of transcriptome-wide investigations13-17. A focus of many of these studies has been 
identification of potential induced mechanisms of resistance to the given neoadjuvant 
therapy. Little attention has been given to how molecular changes resulting from these 
neoadjuvant therapies might impact on response to subsequent adjuvant treatments. This 
question may have growing importance if response to NAET is to be used to stratify patients 
for assignment to adjuvant chemotherapy8, 9.   
We have an interest in roles of xenobiotic drug pumps in resistance to cancer therapies, and 
have previously shown that expression of Breast Cancer Resistance Protein (BCRP), 
encoded by the ABCG2 gene, can be associated with poor survival after chemotherapy in 
breast cancer18. In this new work, we were interested to assess whether NAET impacted on 
expression of ABCG2/BCRP, and whether this could have implications for subsequent 
adjuvant chemotherapy responses.  
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6Material and methods
Patient selection, ethical approval and immunohistochemistry
Ethical approval for use of patient samples and anonymised data and for the consent 
process used was obtained from Leeds (East) Research Ethics Committee (reference 
06/Q1206/180). Informed consent was obtained when appropriate. Primary breast cancer 
patients treated with neoadjuvant endocrine therapy (NAET) at Leeds Teaching Hospitals 
NHS Trust from 2005-2013 were identified. Criteria for inclusion in our study were NAET 
duration of 1 month to 1 year, NAET alone without combination therapy (for example, 
excluding individuals on the NEO-EXCEL trial who additionally received celecoxib), a 
diagnosis of invasive ductal or lobular carcinoma, Allred score for estrogen receptor 
expression of 7 or 8, no change in NAET regime during treatment, and lack of HER2 
overexpression. In addition, we required that tissue before NAET (diagnostic biopsies) and 
after NAET (resection) was available. This identified a cohort of 51 patients. Relevant clinico-
pathological data are outlined in Table 1. Tissues were sectioned at 5m onto SuperFrost 
Plus slides (Menzel-Glaser, Braunschweig, Germany). Matched biopsy and resection 
samples were placed on the same single slide therefore subsequent staining/analysis 
conditions for the pairs were identical and relative expression between them was directly 
comparable. Immunohistochemistry was performed and quantified exactly as described 
previously18. In brief, sections were dewaxed and rehydrated and further antigen retrieval 
was not necessary. Endogenous peroxidase activity was blocked using H2O2. BCRP staining 
was performed with clone BXP-21 (Abcam, Cambridge, UK), which has been used and 
validated in clinical breast tissue previously by us and others18, 19, at 1:50 for 16h at 4oC. 
BCRP staining was visualised using Envision reagents (Dako, Gostrup, Denmark) and 
sections were counterstained in Mayer’s haematoxylin. Sections were digitally scanned 
using Scanscope XT and were analysed using Imagescope (Aperio, Vista, USA). Staining 
was assessed under guidance of breast histopathologists (AMH and ETV). Positive (brown) 
staining was quantified in tumour cells only by weighted histoscores using a semi-automated 
protocol, validated extensively previously18. In brief, tumour epithelial regions were manually 
marked on digital images and positive staining was quantified within these using the positive 
pixel count algorithm in three intensity ranges to ape manual scoring (counts of <100 defined 
as weakly positive, 100 to <175 as moderate, and <=175 as strong). Percentages of total 
pixels categorized into each intensity band were used to determine automated histoscores: 
(1x% weakly positive pixels)+(2x% moderate)+(3x%strong).
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7Cell culture and drug treatments
T47D cells were obtained originally from the European Collection of Animal Cell Cultures. 
Cell line identity was confirmed (STR profiles, Leeds Genomics Service) and cells were 
consistently negative for mycoplasma (MycoAlert Mycoplasma detection assay, Lonza, 
Basal, Switzerland). Cells were cultured in DMEM supplemented with 10% foetal calf serum 
and 1% penicillin/streptomycin (reagents from Thermo Fisher, Waltham, USA). Cells were 
treated with final concentrations of 1M or 5M tamoxifen (Sigma, Poole, UK) or appropriate 
amounts of ethanol (the vehicle for tamoxifen), namely 0.1% (v/v) or 0.5% (v/v) ethanol and 
incubated as normal.
Harvesting protein and RNA
Cells were harvested using trypsin and divided, with three-quarters of the cells to be used for 
protein extraction and the remainder used for RNA extraction. Cells were washed with 
phosphate buffered saline (PBS). For protein extraction, cells were washed again with PBS 
before being lysed for fifteen minutes on ice in RIPA buffer (10mM Tris-HCl, 140mM NaCl, 
0.1% SDS, 1% Triton X-100, 0.1% sodium deoxycholate) supplemented with the chelating 
agents EDTA and EGTA and the protease inhibitor PMSF (Sigma, Poole, UK). RNA 
extraction was performed using Promega’s (Madison, USA) RNA extraction kit using the 
manufacturer’s instructions. In brief, cells were lysed in BL buffer supplemented with thio-
glycerol. Isopropanol was added and the sample added to a spin column. Samples were 
washed and treated with DNase I before being eluted in nuclease-free water.
Expression analyses (SDS-PAGE and western blotting; qPCR)
SDS-PAGE and transfers were performed as described previously20 using 4-12% Bis-Tris 
gels, PVDF membrane, and other reagents from Thermo Fisher (Waltham, USA). After 
transfer, membranes were blocked in 1 or 5% milk in TBS-T. Antibodies were diluted in 1% 
milk/TBS-T. Primary antibodies (anti-beta-actin, 1:10000, Sigma, Poole, UK) or anti-BCRP 
(clone BXP-21, 1:250, Abcam, Cambridge, UK) were incubated overnight at 4oC followed by 
washing with TBS-T then incubation with the secondary antibody (anti-mouse HRP 
conjugate, 1:2000, Abcam, Cambridge, UK) for 1h. Blots were visualised using SuperSignal 
West Pico (Thermo Fisher, Waltham, USA) and Bio-Rad Gel Doc Imaging system, and 
quantified using Image Lab software (version 5.2.1). Reverse transcription of RNA was 
performed using the GoScript Reverse Transcription System (Promega, Madison, USA) 
according to the manufacturer’s instructions. In brief, total RNA was diluted in nuclease-free 
water before incubation with random primers at 70oC for 5min. A reaction buffer mixture 
including reverse transcriptase and nucleotides was then added and the reactions were 
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8placed in a controlled temperature heat block at 42oC to allow reverse transcription to occur. 
Quantification of mRNA levels of the control (beta-actin) and the gene of interest (ABCG2) 
was performed using the GoTaq qPCR Master Mix kit (Promega, Madison, USA) according 
to the manufacturer’s instructions. In brief, a total volume of 10l was plated in a 96-well 
plate containing diluted cDNA, CXR Reference Dye, GoTaq qPCR Master Mix and forward 
and reverse primers for each gene of interest (actin: 5’-TTCTACAATGAGCTGCGTGTG-3’ 
and 5’-GGGGTGTTGAAGGTCTCAAA-3’; ABCG2: 5’-CAGGTGGAGGCAAATCTTCGT-3’ 
and 5’-ACACACCACGGATAAACTGA-3’). Reactions were performed in the ABI 7500 qPCR 
machine (Thermo Fisher, Waltham, USA).
Cell viability assay (MTT)
After 15 days of treatment with tamoxifen, fresh media was placed on the cells for 24h. Cells 
were then trypsinised and plated into 96 well plates (Corning, New York, USA). Cells were 
left for another 24h before being treated with 2.6M or 10M epirubicin (Sigma, Poole, UK) 
or water (the vehicle for epirubicin), and incubated as normal for a further 24h. MTT assays 
(Thermo Fisher, Waltham, USA) were then performed as previously described21, with 
readings taken using the Mithras LB 940 Multimode Microplate Reader (Berthold 
Technologies, Harpenden, UK).
Cell cycle analysis
After pre-treatment with tamoxifen, cells were given fresh media for 24h. Cells were then 
fixed in 70% ethanol for 2h. Cells were washed then resuspended in PBS before addition of 
propidium iodide (Sigma, Poole, UK) at 0.02mg/ml and RNase A (Thermo Fisher, Waltham, 
USA) at 0.4mg/ml. After incubation for 20min at room temperature in the dark, cell cycle 
status was analysed using the Attune Acoustic Focusing Cytometer (Thermo Fisher, 
Waltham, USA) and accompanying Attune Cytometric Software Version 2.1.
Analysis of publicly available gene expression datasets
Microarray data from related breast cancer studies looking at primary tumours or cell lines 
were downloaded from NCBI Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/). 
Primary tumour datasets looking at the effects of 2 weeks and 3 months of letrozole from 
Edinburgh (GSE20181) and 2 weeks of an unspecified aromatase inhibitor in Houston 
(GSE87411) were considered, along with a dataset of breast tumours that were untreated 
between diagnosis and surgery, again from Edinburgh (GSE76728). Gene expression data 
on MCF7 breast cancer cell line following tamoxifen-treatment (GSE21618) and long term 
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9estrogen deprivation (GSE20361) were also considered. Normalised pre-processed data 
was used in all cases.
Results
ABCG2/BCRP is up-regulated post-NAET in breast cancer patients
We were interested to study changes in expression patterns in primary breast tumours 
induced by NAET. Since we have previously studied xenobiotic drug pumps that are known 
to impact on outcomes in breast cancer18, 20, we focused on one of these pumps - 
ABCG2/BCRP. We identified a cohort of fifty-one breast cancer patients treated with NAET 
in Leeds and for whom tumour tissue was available from both pre-NAET (diagnostic 
biopsies) and post-NAET (resection tissue). Clinico-pathological details of these patients are 
shown in Table 1. We detected BCRP using immunohistochemistry and quantified 
expression objectively using an automated scoring system, as previously described18. 
Representative staining in a matched pair of pre- and post-NAET samples is shown in Fig 
1A, while expression levels in all samples are shown in Fig 1B, with lines indicating the 
matched samples from individual patients for comparison. Expression was up-regulated after 
NAET in 48/51 (94%) cases and up-regulation was significant overall (p<0.0001; Fig 1B). To 
confirm whether ABCG2 was increased in other breast cancer cohorts following endocrine 
treatment, we examined published microarray mRNA expression datasets of matched 
samples from breast cancer patients, taken before and after aromatase inhibitor treatment. 
Levels of ABCG2 was found to be up-regulated after NAET in the majority of patients in two 
cohorts from Edinburgh and Houston14, 15 after two weeks and three months, and up-
regulation was significant (p<0.01 in all cases, paired Wilcoxon). By way of a negative 
control, ABCG2 expression was not significantly changed (p=0.12) in a cohort of 37 breast 
tumours that did not receive treatment between diagnosis and surgery22 (Fig 1C), where the 
interval ranged from 13 to 53 days (mean 27.5 days).
ABCG2/BCRP is up-regulated by tamoxifen in estrogen receptor positive breast 
cancer cell lines
Having determined that ABCG2/BCRP is up-regulated post-NAET in patients, we were 
interested to investigate whether this could be reproduced in vitro using a breast cancer cell 
line, and if so, what the implication of this might be. Therefore, we treated the ER-positive 
cell line T47D with the endocrine therapeutic tamoxifen and examined BCRP/ABCG2 
expression using Western blots and/or qPCR. BCRP was up-regulated as quickly as 7h after 
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10
treatment with1M tamoxifen (Fig 2A), and this up-regulation increased with up to 3 days of 
continuous treatment (Fig 2B). Significant and dose-dependent up-regulation of both 
transcript (ABCG2) and protein (BCRP) was evident after 15 days of continuous tamoxifen 
treatment at 1 and 5M (Fig 2C). Using publically available datasets23, 24, we have also 
shown up-regulation of ABCG2 in response to 1M tamoxifen treatment and in response to 
estrogen (E2) withdrawal in another ER-positive cell line, MCF7 (Fig 2D), suggesting that our 
findings are not limited to T47D cells. Physiological intra-tumoural concentrations of 
tamoxifen have been estimated as between 0.5 to 2M25-27, therefore these doses used in 
vitro are within an appropriate range.
Tamoxifen pre-treatment leads to resistance to subsequent chemotherapy in vitro 
Increased ABCG2/BCRP expression can be associated with resistance to many standard 
cytotoxic chemotherapeutics28, 29, so we were next interested to assess whether tamoxifen-
induced changes in ABCG2/BCRP expression would have an impact on subsequent chemo-
response. Therefore, we again treated cells with control or two different doses of tamoxifen 
(1 or 5µM) for fifteen days, before removing tamoxifen and treating with control or two 
different doses of epirubicin (2.6 or 10µM), an anthracycline chemotherapeutic drug 
frequently used in breast cancer treatment and known to be an AGCG2 substrate 30. 
Relative cell survival was determined using MTT assays (Fig 3A). In cells without tamoxifen 
pre-treatment (black bars), epirubicin treatment caused a dose-dependent reduction in cell 
survival of up to 76%. Pre-treatment with either dose of tamoxifen increased cell survival 
from epirubicin, most notably the higher tamoxifen dose giving significant protection from 
10µM epirubicin (p<0.05) with increased survival by more than 2-fold.
One explanation for the chemoresistance shown by cells pre-treated with tamoxifen would 
be that tamoxifen-induced exit from cell cycle was providing protection from the effects of 
epirubicin, which at least in part targets cells undergoing DNA replication. In order to support 
or refute this hypothesis, we next examined the influence of 15 days of tamoxifen treatment 
on the cell cycle in T47D cells using propidium iodide staining and flow-cytometry (Fig 3B). 
There were no significant alterations in the cell cycle profile of tamoxifen pre-treated cells, 
providing no support for the hypothesis that cell cycle changes were responsible for the 
increased chemoresistance. In this context, we believe our data support a direct functional 
role for BCRP up-regulation in chemoresistance after endocrine treatment.
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Discussion
Here, we present the first study to address the influence of NAET on ABCG2/BCRP 
expression in clinical cohorts of breast cancers. A number of previous studies have 
assessed the impact of estrogens on ABCG2/BCRP expression in breast cancer cell lines31-
33. Unfortunately, published data are conflicting, and there is no clear consensus concerning 
whether estrogens stimulate or repress expression across a range of cell lines. For example, 
it has been reported that treatment with estradiol repressed BCRP expression in ER-positive 
breast cancer cells lines, including T47D as used in our study31, findings that are compatible 
with our observations that blocking estradiol function with tamoxifen resulted in 
ABCG2/BCRP up-regulation. However, by contrast, others have shown estradiol to induce 
transcriptional up-regulation of ABCG2 at one of its promoters in T47D cells as well as other 
ER-positive cancer lines32, and the anti-estrogen toremifene to repress both ABCG2 mRNA 
and BCRP expressions in ER-positive MCF7 cells33. This literature likely reflects the 
complexity of ABCG2/BCRP regulation in different cell types and under different culture 
conditions34. Nevertheless, our clinical observation that BCRP up-regulation in 48/51 
patients after NAET is highly consistent and statistically significant in our Leeds cohort, and 
in all other available relevant clinical datasets (Fig 1). The up-regulation of BCRP we 
observe after tamoxifen treatment in T47D cells (Fig 2) is compatible with all studies in this 
cell line that have looked at endogenous protein, and similar increases in ABCG2 were 
observed for tamoxifen treatment or E2 withdrawal in MCF7 cells.  
A concerning conclusion from these observations is that NAET-induced up-regulation of 
ABCG2/BCRP could potentially reduce the efficacy of adjuvant chemotherapy treatment in 
breast cancer patients. We have attempted to model this effect using T47D cells, in which 
ABCG2/BCRP is up-regulated after initial treatment with tamoxifen. We find clear evidence 
that pre-treatment with tamoxifen protects the cells from chemotherapy, and this appears to 
be independent of any cell cycle effects (Fig 3). Unfortunately, the hypothesis that patients 
who received NAET respond relatively poorly to adjuvant chemotherapy is not easy to test 
using existing clinical data since treatment with NAET followed by adjuvant chemotherapy is 
currently an uncommon clinical pathway. From our initial Leeds cohort of 51 patients in 
which we examined BCRP expression pre- and post-NAET, only 6 patients received 
adjuvant chemotherapy. From the Edinburgh cohort of 55, only 2 received adjuvant 
chemotherapy. Therefore, outcome data on a large enough number of patients are not 
available to evaluate the effect of NAET on adjuvant chemotherapy. Furthermore, it is not 
clear what represents a suitable comparator group to allow relative assessment of 
chemotherapy response, since patients who receive NAET are typically deemed suitable for 
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this therapy for specific clinical reasons that likely mean they are not usefully comparable to 
other groups. A formal randomised clinical trial may be the only way to allow a robust 
assessment of whether NAET negatively influences responses to adjuvant chemotherapy; 
such a trial is unlikely and even if it took place outcomes would not be known for many years 
as these ER-positive cancers overall have good prognoses and recurrences tend to be late. 
However, the potential for NAET to impair responses to chemotherapy may well be worth 
noting for the future, particularly in the context that it has been suggested that response to 
NAET could be a useful tool to stratify patients to adjuvant chemotherapy8, 9, and some have 
combined endocrine therapy with chemotherapy in the neoadjuvant context35. Our results 
suggest that analyses of outcomes with these approaches in the future is warranted.
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Characteristic Categories No. of patients (%)
n=51
Age Median: 67 years old
(range 40-95 years old)
IDC 38 (74.5)
ILC 7 (13.7)
Histological type
IDC/ILC 7 (13.7)
1 15 (29.4)
2 30 (58.8)
Grade 
3 6 (11.8)
T1         17 (33.3)
T2 26 (51)
T3 5 (9.8)
Stage (pre-NAET)
T4 3 (5.9)
T1 19 (37.3)
T2 25 (49)
Stage (post-NAET)
T3 7 (13.7)
Increase or no change           22 (43.1)Tumour size change
Decrease  29 (56.9)
Lymphovascular invasion               Positive           11 (21.6)
ER 51 (100)Receptor status (4/8 as 
cut-off for positive 
expression) 
   PR 37 (78.7)
NAET duration Median: 90 days
(range 30-362 days)
Anastrozole 24 (47.1)
Letrozole 20 (39.2)
NAET regimen
Tamoxifen 7 (13.7)
Axillary metastasis Positive 21 (41.2)
breast conserving 22 (43.1)Surgery
Mastectomy 29 (56.9)
Table 1. Clinico-pathological characteristics of the breast cancer patients 
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Fig 1 BCRP expression is increased in patients post-NAET. 51 matched pre- and post-
NAET breast tumour samples were stained for BCRP using immunohistochemistry and 
expression was quantified using automated histoscores. (A) Representative images of a 
matched pre- and post-NAET tissues showing BCRP expression (brown). (B, left) Individual 
scores for pre- and post-NAET tissues with lines connecting the matched samples. Red lines 
indicate increases in BCRP expression and blue lines indicate decreases. (B, right) Median 
histoscore values with interquartile range (significance assessed using the Wilcoxon signed 
rank test). (C) Expression of ABCG2 (the transcript encoding BCRP) was assessed using 
expression microarrays in pre-NAET samples and matched post-NAET breast cancer 
samples in two separate cohorts of patients. In the Edinburgh cohort (n=55), patients were 
treated with letrozole and change in expression assessed after 2 weeks (2w) and 3 months 
(3m). In the Houston cohort (n=94), patients were treated with aromatase inhibitors (no 
information as to which) and change in expression was assessed after 2 weeks (2w). 
Expression was also assessed in matched diagnostic biopsy and surgical excision samples 
from breast cancer patients who received no intervening treatment (“no T”; n=37). 
Expression in later samples is shown relative to the first as log2 fold change, with red and 
blue indicating up- or down-regulation respectively. Median change in expression is shown 
by the black line, boxes show the upper and lower quartiles, and whiskers 1.5x the 
interquartile range. Significance of changes in expression was assessed using paired 
Wilcoxon tests.   
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Fig 2 ABCG2/BCRP is up-regulated by tamoxifen in ER-positive breast cancer cells. 
(A-C) T47D cells were treated with 1µM or 5µM tamoxifen or vehicle control (100% ethanol) 
for the indicated lengths of time (vehicle control at the longest timepoint) before analysis for 
BCRP protein expression (western blot and densitometry) or ABCG2 transcript expression 
(qPCR). (A) BCRP expression was determined after a single dose of 1µM tamoxifen. A 
representative western blot is shown on the left and the accompanying histogram depicting 
relative BCRP expression on the right. (B) BCRP expression was determined after a single 
dose of 1µM tamoxifen. A representative western blot is shown on the left and the 
accompanying histogram depicting relative BCRP expression on the right. (C) Cells were 
treated daily with either 1µM or 5µM tamoxifen for fifteen days. The left plot shows a 
representative western blot. The middle plot shows densitometry of relative BCRP 
expression (independent experiments n=2, +/- SEM). The right plot shows relative ABCG2 
expression (independent experiments n=3, +/- SEM). (D) MCF7 cells were treated with 1µM 
tamoxifen or were deprived of estrogen and gene expression was assessed at various 
timepoints using expression arrays23, 24. ABCG2 expression is shown relative to untreated; 
the left plot shows effect of tamoxifen treatment while the right plot shows effect of estrogen 
deprivation at the timepoints indicated.
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Fig 3 Pre-treatment with tamoxifen induces relative chemoresistance. T47D cells were 
treated with either tamoxifen (1M or 5M) or vehicle control (100% ethanol) daily for fifteen 
days. (A) Tamoxifen or control was then removed, and cells were treated with 2.6µM or 
10µM epirubicin or vehicle control (water) for 24h before relative survival was determined 
using MTT assays. The left panel shows a representative graph of the effects of epirubicin 
on viability of cells following pre-treatment with TAM. Error bars show the standard deviation 
of three technical repeats. The right panel shows 2 biological repeats (+/- SEM) of the 
experiment depicted in the left panel, normalising the tamoxifen pre-treated data to the 
control-pre-treated sample for each dose of epirubicin, to allow focus on the differences 
between tamoxifen pre-treated vs without tamoxifen pre-treatment. (B) After 15 days of pre-
treatment with 5M tamoxifen or vehicle control, cells were stained with propidium iodide 
and analysed with by flow cytometry to determine proportions of cells in each of the three 
cell cycle stages. Error bars represent SEM of two biological repeats.
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